NEO - CONSENSUS CO - NeoGenomics, Inc.

The current market quotes on GURU.Markets visualized below confirm the resilience of NeoGenomics, Inc. (NEO) cash flows, which are based on the demand for oncology diagnostics. The indicator stands at 19.77. The business relies on a network of modern American laboratories, where strict adherence to sterility guarantees the accuracy of analyses. Currently, NeoGenomics, Inc. (NEO) is focusing on organic growth and updating its test menu, deliberately eschewing mergers in favor of partnerships with pharma behemoths.

This metric aggregates investment bank forecasts, neutralizing the time gaps between quarterly reports. It determines the fundamental value potential of the asset via a weighted average target price. For NeoGenomics, Inc. (NEO), a steady stream of orders from clinics confirms the stability of this calculation. The current average target price for the stock stands at 19.77. The dynamics of this indicator allow investors to promptly assess marginal risks and the probability of a correction.